S&P/TSX Composite Index (STAR)
N/A
Reasons to love Canada: 1) No ICE agents terrorizing communities; 2) Consumers will soon have access to highly rated, reasonably priced Chinese electric vehicles, thanks to a new trade deal with Beijing; 3) After rising nearly 29 per cent in 2025 – its biggest gain since 2009 – Canada’s benchmark S&P/TSX Composite Index is off to a flying start in 2026, surging more than 4 per cent so far this year.
Cineplex Inc. (DOG)
Attention film buffs: The pandemic is over. It’s safe to go back to theatres now. Apparently, some folks haven’t gotten the memo yet, judging by the nearly 5-per-cent drop in Cineplex’s box-office receipts for the fourth quarter. With October and November getting off to a slow start and the latest instalment of the Avatar franchise underperforming expectations, Canaccord Genuity analyst Aravinda Galappatthige cut his target on Cineplex shares to $11.50 from $13. Well, at least Cineplex is bringing back $5 Tuesdays. If that doesn’t put bums in seats, nothing will.
Titanium Transportation Group Inc. (STAR)
As the Grateful Dead sang: “Truckin’, got my chips cashed in.” After a tumultuous 2025 marked by tariff uncertainty and soft demand, Canadian trucking firm Titanium Transportation Group is giving investors a chance to cash in for $2.22 a share – a 41-per-cent premium to the price before the offer was announced. The proposed privatization, led by company management and long-time shareholder Trunkeast Investments Canada, will be put to a shareholder vote in March. Judging by the stock’s 38-per-cent gain on the news, investors are set to take the money and roll on down the highway.
Spotify Technology S.A. (DOG)
Music streaming giant Spotify Technology is notorious for paying peanuts to its artists. But it’s not shy about asking subscribers to dig deeper to pay for its service. In a move that sent the shares down, Stockholm-based Spotify said it will raise the price of its premium, ad-free service in the U.S. by a dollar to $12.99 – the third increase in four years – “enabling us to continue offering the best possible experience and benefit artists.” But with the share price down about 13 per cent this year following a 30-per-cent gain in 2025, investors don’t seem to like what they’re hearing.
BriaCell Therapeutics Corp. (DOG)
Pop quiz! Shares of BriaCell Therapeutics plunged when the biotech company: a) suspended a clinical trial of a cholesterol drug after patients broke into the robot dance following their first dose; b) was targeted by a short seller who alleged BriaCell’s “clinical data” was actually a spreadsheet containing NFL passing and rushing stats; c) priced a US$30-million public offering of units – each consisting of one common share and one warrant – at US$5.59 a unit, or nearly 50 per cent below the stock price before the offering was announced. Answer: c.